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Gy) followed by 3 weekly applications of intraluminal high 
dose rate brachytherapy (HDRBT)starting 6 weeks after EBRT. 
The starting dose level was 3x5 Gy with escalation of 1 Gy 
per fraction if acute toxicity was acceptable. Toxicity was 
acceptable if <2/6 patients or <3/9 patients exhibited dose 
limiting toxicity (DLT), defined as grade 3 proctitis (CTCAE v 
3.0), within 6 weeks after HDRBT. Secondary endpoints were 
severe treatment-related late toxicity, clinical tumor 
response and progression free survival (PFS). Clinical tumor 
response was evaluated based on all available endoscopy 
pictures and defined as complete clinical response (CR), 
partial response (PR), stable disease (SD) or progression (PD). 
 
Results: Thirty-eight patients with a mean age of 81 years, 
entered the study of whom 36 received HDRBT. Two patients 
died directly after HDRBT and 3 patients refused follow-up 
endoscopies, leaving 31 patients for response evaluation. At 
time of current analyses 13 patients were still alive, with a 
median FU of 30 months. Primary endpoint was reached at 
the 8 Gy dose-level with 3/9 patients showing a DLT. 
Response was observed in 25 patients (80.6%); of the 18 
patients achieving a CR, 6 developed progressive disease 
later on. Of the 7 patients with PR, 4 showed progression, 
whereas this occurred in 5/6 patients with SD. Median time 
to progression was 6.3 months. PFS at 1,2 and 3 years was 
65.6%, 46.4% and 22.1% respectively. Late treatment related 
grade 3/4 toxicity occurred in 13 patients, of those 9 patients 
also showed progressive disease. Outcomes related to 
doselevel are displayed in table 1. 
 
 
Conclusion: A combination of EBRT and HDRBT is feasible in 
inoperable elderly patients with acceptable acute toxicity 
and a promising overall response rate of 80.6%. However, 
given the observed toxicity, a randomized trial comparing 
EBRT with or without HDRBT boost is necessary. In this trial 
the clinical relevance of the added tumor control in light of 
additional toxicity from HDRBT will be evaluated in this 
fragile population. 
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Purpose or Objective: Radiation therapy is an established 
neoadjuvant modality for patients with advanced rectal 
cancer. As the quality of surgery improved with Total 
Mesorectal Excision surgery (TME), radiation is now being 
challenged, as the number of patients needed to treat 
remains high when facing long-term normal tissue toxicity in 
the pelvis. High dose rate endorectal brachytherapy is a 
highly targeted form of radiation based on quality imaging 
with magnetic resonant imaging and was introduced in our 
institution along with TME. Unlike external beam radiation 
therapy, the clinical target volume is aiming mostly at the 
tumor bed. We are reporting the patterns of relapse of our 
patients after 15 years experience. 
 
Material and Methods: Patients with operable rectal cancer 
based on pelvic MRI staging, are considered at risk for local 
recurrence were included; for physical reasons, those with 
obstructive tumors and positive extramesorectal nodes were 
excluded. Patients received treatment with 26 Gy in 4 
fractions using a remote afterloader with an endoluminal 
cylindrical multichannel applicator and an Iridium 192 
source. The CTV is defined as the gross tumor volume 
observed on the diagnostic MRI with no attempt to cover the 
perirectal nodes. 667 patients treated from 1999-2015, most 
of which were T3 tumors (84%), low T2 (13%) and early T4 
(3%); 36 % of the patients had positive nodes on pre-operative 
imaging. The local failure in our patient population is 4.7 % 
with a median follow up time of 65 months for 608 patients 
(range 6-165 months). Twenty-eight patients had pelvic 
recurrence, of which 25 were documented with MRI and 3 
were found with CT scan. The Imaging was reviewed by two 
radiologists. 
 
Results: The location of recurrence were identified as: iliac 
or lateral nodes in 11 patients, anastomotic in 10 patients, 
inguinal nodes in 3 patients, anterior compartment in 4 
patients and pre-sacral space in one patient (one patient had 
more than 2 sites). In the patients with nodal pelvic relapses, 
the relapse was isolated for 3 patients and in the other 8 
patients there were associated systemic relapses, and these 
patients were asymptomatic and did not require pelvic 
radiation while the former 3 patients underwent successful 
salvage radiation with IMRT (1) /SBRT for 2 patients. Another 
9 patients with isolated pelvic relapses received pre-
operative pelvic radiation with salvage surgery. 
 
Conclusion: In patients with rectal cancer treated with pre-
operative HDRBT, pelvic nodal relapse was the most common 
site of recurrence and was often associated with 
asymptomatic systemic relapse. Those patients with isolated 
nodal relapse are salvageable with either IMRT of SBRT. For 
patients with localized recurrence, pre-operative pelvic 
radiation was possible with salvage surgery. Pre sacral 
recurrence is a rare event, with a single patient observed. 
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Purpose or Objective: Locally advanced unresectable biliary 
carcinoma often present as extrahepatic malignant biliary 
obstruction with jaundice. The aim of treatment is to relieve 
jaundice and pruritus either by endoscopic biliary drainage 
(EBD) or percutaneous transhepatic biliary drainage (PTBD) 
followed by stenting. Stent is frequently blocked due to 
either tumour ingrowth or overgrowth. Intraluminal 
brachytherapy (ILBT) allows high dose to of radiation to local 
tumor area and delays the stent block. The purpose of this 
study is to assess the safety and efficacy of ILBT and impact 
of external beam radiotherapy(EBRT) on stent patency and 
survival. 
 
Material and Methods: From 1998-2008, 172 unresectable, 
locally advanced biliary cancers (pancreas-12, gallbladder-
140, cholangiocarcinoma-20), presenting with malignant 
extrahepatic biliary obstruction were prospectively treated 
with PTBD and stenting followed by ILBT with or without 
EBRT. The 110/172(64%) patients received ILBT alone (ILBT 
group) while 62/172(36%) received ILBT followed by 
EBRT(EBRT group). Endoscopic retrograde cholangio 
pancreaticography (ERCP) and/or percutaneous 
cholangiogram (PC) was done in all. Biliary drainage was done 
by standard ultrasound and fluoroscopy guided percutaneous 
transhepatic puncture. The stricture was dilated by balloon 
catheter over the guide wire. The biliary tract was dilated 
repeatedly and upsized till 12 French Malecot catheter. High 
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dose rate brachytherapy with Ir192 source used to deliver 10 
Gy/1fr at 1 cm radius from the center of source. PTBD tube 
was replaced by 10 mm, non sheathed self expandable 
metallic modified Giantruco Z stent. In EBRT group, stenting, 
followed by EBRT(dose of 45Gy/25fr/ 5 weeks) by conformal 
technique to primary tumour and stent area. All the patients 
were given single agent 5-Fluorouracil chemotherapy 370 
mg/m2 Day1-5 at 4 weekly for 6 cycles. 
 
Results: Palliation of jaundice and pruritus was achieved in 
all. The median overall survival in ILBT and EBRT group was 8 
and 9 months with the stent patency 7 and 8 months and 
overall survival at 1 year was 21% and 23%. Gastric outlet 
obstruction was 29% in ILBT group and 19% in EBRT 
group(p=ns), while distant failure rate were 60 % & 55%. No 
ILBT related morbidity was observed. 
 
Conclusion: PTBD is safe, well tolerated and effective in 
palliation of Jaundice. Intraluminal Brachytherapy (ILBT) 
appears to prolong stent patency The addition of EBRT to 
ILBT does not show any advantage in terms of stent patency 
and overall survival. 
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Purpose or Objective: In a retrospective study of 100 
consecutive patients treated with Ru-106 eye plaques for 
uveal melanoma from 2005 to 2008 at our clinic, we aimed to 
investigate the correlation between the dose to the optic 
nerve and optic nerve damage; the dose to the macula and 
macular damage; and the minimum dose to the tumour and 
tumour control.  
 
Material and Methods: Pre-treatment fundus images were 
imported into Plaque Simulator TM and the tumour was 
retrospectively contoured by an ophthalmologist. The plaque 
position was determined from the radiation scar on post-
treatment images. 3D dosimetric data was calculated. The 
point doses to the optic nerve and macula and minimum dose 
to the tumour were estimated. TCP, and damage to the optic 
nerve and macula, were determined from the patients’ 
notes. The correlations between optic nerve damage, 
macular damage and TCP with dose, dose rate, gender, and 
plaque type was investigated using univariate and 
multivariate analyses. 
 
Results: 16 % of the patients developed optic nerve damage. 
Only optic nerve dose was correlated with damage to the 
optic nerve (p=0,000063) in univariate analysis.  
51% of the patients had macular damage. Only macular dose 
was correlated with damage (p=0,00049) in univariate 
analysis.  
32 % of the patients did not achieve tumour control. TCP was 
correlated with minimum tumour dose and gender in 
univariate analysis. Patients with minimum doses > 80 Gy had 
100% TCP.For 80% of the patients with tumour recurrence, 
the plaque did not geometrically overlap the tumour.  
Dose response curves were drawn for optic nerve damage, 
macular damage and TCP. Such curves could not be found in 
the literature so no comparison was possible. Previously 
published values for TCP are similar to, or higher than, the 
one found in the present material. However, the papers 
citing higher values have selected patients with smaller 
tumours, which tend to have higher values of TCP. We 
emphasise that the number of patients is quite small and that 
a study of a large patient cohort is planned.  
 
Conclusion: Tumour control only failed in patients who 
received less than the prescription dose. The use of image 
guided planning software (such as Plaque Simulator TM) may 
aid in optimizing tumour control in the future. The present 
analysis presents the first reported dose response curves for 
damage to the optic nerve and macula. This information may 
be useful in delivering the optimal treatments in future.  
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Purpose or Objective: Treatment of uveal melanoma by 
means of brachytherapy using 106Ru eye plaques achieves 
very good tumor control while keeping morbidity at an 
acceptable level. However, a deeper understanding of the 
underlying dose-response relationship is still missing not least 
because of the lack of appropriate software packages for 3D 
treatment planning and volumetric dose assessment. This 
motivated the in-house development of software modules to 
calculate the dose distributions in critical, ophthalmologic 
structures as well as tumor for an eye model. 
 
Material and Methods: A resizable 3D model of an eye was 
created in Sidefx Houdini, consisting of lens, ciliary body and 
optic nerve as well as macula, retina and sclera. A dome-
shaped tumor model can be added with apex height and basal 
diameter as adjustable parameters. The position of the 
tumor model can be fixed by reference to the distance 
between tumor and macula and tumor and optical nerve. 
Alternatively fundus images can be incorporated into the 3D 
model in order to account for the individual tumor shape. A 
specially designed algorithm projects the images onto the 
virtual eye model and converts them to volumetric data. 
Different types of BEBIG eye plaques (CCA, CCB and COB) can 
be positioned within the computer model. Corresponding 
dosimetric lookup tables were generated from MC simulations 
using MCNP6. Superposition onto the 3D eye model enables 
the calculation of doses and dose volume parameters for the 
tumor and adjacent healthy tissue. Finally, dosimetric safety 
margins have been obtained by performing film 
measurements and can be included in order to determine 
dosimetric uncertainties. 
 
Results: The software modules can calculate full 3D dose 
distributions with a cubic dose grid of 200 µm in < 5 s (and < 
1 s with GPU). The 3D eye model can be adjusted on the 
basis of simple geometric measures such as the measured size 
of the eye as well the distances between tumor, macula and 
optic nerve and thereby be used for individual treatment 
planning, i.e. the selection and positioning of the type of 
plaque. The registered fundus projection can be used to 
guide the tumor delineation. Dose-volume metrics can be 
generated for all structures of the individualized model which 
in turn can be used for assessing dose-response relationships 
for the target volume and organs-at-risk. The dosimetric 
uncertainty assessment provides information on safety 
margins. Local agreement between MC and film was better 
than 6 % for the first 7 mm. 
 
Conclusion: In this study we presented novel software 
modules for treatment planning in 106Ru eye plaque 
brachytherapy of uveal melanomas. It is aimed to be used in 
daily treatment planning as well as for performing pro- and 
retrospective studies to provide further information on dose-
response relationships and prognostic values for treatment 
morbidity and local control. Future works involves the 
registration of pre- and/or post-application MR images as 
